SLN Key Statistics, Chart & Performance
The current stock price of SLN is 4.965 USD. In the past month the price decreased by -20.72%. In the past year, price decreased by -9.57%.
SLN Technical Analysis
SLN Financial Highlights
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | N/A | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
SLN Forecast & Estimates
SLN Ownership
About SLN
Company Profile
Silence Therapeutics PLC is a GB-based company operating in Biotechnology industry. Silence Therapeutics plc is a global clinical-stage biotechnology company engaged in transforming people’s lives by silencing diseases through precision-engineered medicines created with proprietary siRNA (short interfering RNA) technology. The firm leverages its mRNAi GOLD platform to create siRNAs designed to precisely target and silence disease-associated genes in the liver. The firm focuses on areas of high unmet medical need with programs advancing cardiovascular disease, hematology and rare diseases. Divesiran (SLN124) is its wholly owned siRNA product candidate designed to inhibit TMPRSS6 expression in the liver. Zerlasiran is a siRNA molecule designed for the treatment of cardiovascular disease associated with elevated Lp(a), a lipoprotein in the blood. In addition to its wholly owned clinical pipeline, it has a third siRNA product candidate from its mRNAi GOLD platform in Phase I development in an undisclosed indication through its collaboration with AstraZeneca.
Company Info
SILENCE THERAPEUTICS PLC-ADR
72 Hammersmith Road
London W14 8TH GB
CEO: Mark Rothera
Employees: 115
Phone: 442034576900
SILENCE THERAPEUTICS PLC-ADR / SLN FAQ
What does SLN do?
Silence Therapeutics PLC is a GB-based company operating in Biotechnology industry. Silence Therapeutics plc is a global clinical-stage biotechnology company engaged in transforming people’s lives by silencing diseases through precision-engineered medicines created with proprietary siRNA (short interfering RNA) technology. The firm leverages its mRNAi GOLD platform to create siRNAs designed to precisely target and silence disease-associated genes in the liver. The firm focuses on areas of high unmet medical need with programs advancing cardiovascular disease, hematology and rare diseases. Divesiran (SLN124) is its wholly owned siRNA product candidate designed to inhibit TMPRSS6 expression in the liver. Zerlasiran is a siRNA molecule designed for the treatment of cardiovascular disease associated with elevated Lp(a), a lipoprotein in the blood. In addition to its wholly owned clinical pipeline, it has a third siRNA product candidate from its mRNAi GOLD platform in Phase I development in an undisclosed indication through its collaboration with AstraZeneca.
What is the stock price of SILENCE THERAPEUTICS PLC-ADR today?
The current stock price of SLN is 4.965 USD. The price increased by 3.01% in the last trading session.
Does SILENCE THERAPEUTICS PLC-ADR pay dividends?
SLN does not pay a dividend.
What is the ChartMill rating of SILENCE THERAPEUTICS PLC-ADR stock?
SLN has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 0 out of 10.
Can you provide the upcoming earnings date for SILENCE THERAPEUTICS PLC-ADR?
SILENCE THERAPEUTICS PLC-ADR (SLN) will report earnings on 2026-02-27, before the market open.
Who owns SILENCE THERAPEUTICS PLC-ADR?
You can find the ownership structure of SILENCE THERAPEUTICS PLC-ADR (SLN) on the Ownership tab.